Tag
A major AHA scientific statement forecasts a significant increase in cardiovascular disease and risk factors among U.S. women by 2050. It highlights rising rates of obesity and hypertension while emphasizing the urgent need for targeted int
This article examines the CHIIP study, a randomized clinical trial evaluating whether survivorship care plan-based counseling improves cardiovascular risk factor control in childhood cancer survivors. Findings suggest that while documentati
A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional
A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic
A FIELD sub-study reveals that while higher haptoglobin levels increase cardiovascular risk—particularly in those with the HP 1-1 phenotype—fenofibrate’s protective effects remain consistent regardless of haptoglobin status, challengi
The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite k
Longitudinal data from the Women’s Health Study reveal that elevated Lipoprotein(a) is a potent, independent predictor of myocardial infarction and ischemic stroke over three decades, suggesting a critical need for universal screening in pr
Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with
Recent studies demonstrate that biomarkers of bone metabolism, particularly the OPG/TRAIL ratio, are powerful predictors of cardiovascular disease and mortality in patients with type 2 diabetes and chronic kidney disease, offering improved
Data from the REPRIEVE trial indicates that while general clonal hematopoiesis is common in people with HIV, only large clones (VAF ≥10%) significantly elevate the risk for myocardial infarction and revascularization, independent of traditi
A nationwide target trial emulation study reveals that SGLT2 inhibitors provide cardiovascular benefits across a broader range of patients than previously recognized, with benefit more closely tied to individual metabolic traits than tradit
A large-scale UK Biobank study demonstrates that combining NMR metabolomics, polygenic risk scores, and clinical biomarkers with SCORE2 significantly enhances cardiovascular risk prediction, potentially doubling the number of prevented even
Electronic behavioral nudges significantly improve influenza vaccination rates among patients with chronic and cardiovascular diseases, offering scalable public health strategies.
The FLUNITY-HD pooled analysis of over 466,000 older adults demonstrates that high-dose inactivated influenza vaccine (HD-IIV) significantly reduces hospitalizations for influenza, pneumonia, and cardiovascular causes, including a 21.3% red
A nationwide cohort study demonstrates that maternal pre-existing ASCVD is independently associated with an increased risk of neonatal complications and long-term neurodevelopmental disorders, persisting regardless of adverse pregnancy outc
This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesit
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
This review synthesizes evidence linking adherence to the Planetary Health Diet with reduced risks of myocardial infarction, type 2 diabetes, and improved weight management in women post-gestational diabetes, highlighting BMI’s mediat
Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑fo
